Abstract
AstraZeneca is developing ZD-6126, one of the ANG-400 series of vascular-targeting and tubulin-binding agents under license from Angiogene Pharmaceuticals Ltd, for the potential treatment of cancer.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials as Topic / statistics & numerical data
-
Drugs, Investigational / chemistry
-
Drugs, Investigational / therapeutic use*
-
Humans
-
Neoplasms / drug therapy
-
Organophosphorus Compounds / chemistry
-
Organophosphorus Compounds / therapeutic use*
Substances
-
Antineoplastic Agents
-
Drugs, Investigational
-
N-acetylcochinol-O-phosphate
-
Organophosphorus Compounds